<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10428520
   </pmid>
   <datecreated>
    <year>
     1999
    </year>
    <month>
     09
    </month>
    <day>
     21
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1999
    </year>
    <month>
     09
    </month>
    <day>
     21
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0306-5456
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       106
      </volume>
      <issue>
       7
      </issue>
      <pubdate>
       <year>
        1999
       </year>
       <month>
        Jul
       </month>
      </pubdate>
     </journalissue>
     <title>
      British journal of obstetrics and gynaecology
     </title>
     <isoabbreviation>
      Br J Obstet Gynaecol
     </isoabbreviation>
    </journal>
    <articletitle>
     Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial.
    </articletitle>
    <pagination>
     <medlinepgn>
      652-7
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To test the hypothesis that prophylactic administration of clindamycin 2% vaginal cream can reduce the incidence of preterm birth in a high risk population.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      A multi-centre, randomised, double-blind, placebo-controlled trial.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Twelve city hospitals in The Netherlands.
     </abstracttext>
     <abstracttext label="PARTICIPANTS" nlmcategory="METHODS">
      One hundred and sixty-eight women with a singleton pregnancy and a history of a spontaneous preterm delivery in the preceding pregnancy.
     </abstracttext>
     <abstracttext label="INTERVENTIONS" nlmcategory="METHODS">
      Clindamycin 2% vaginal cream, or placebo cream, administered daily for seven days at 26 and 32 weeks of gestation.
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURES" nlmcategory="METHODS">
      Spontaneous preterm birth at &lt; 37 weeks, admission for threatened preterm labour, neonatal infectious morbidity.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      In the intention-to-treat analysis no difference was found in overall preterm birth between clindamycin and placebo (23% vs 18%, respectively). In the subgroup who completed the trial and administered all medication, more women delivered before 34 weeks in the clindamycin group (1.4% in the placebo vs 9.0% in the clindamycin group; P &lt; 0.05). The length of admissions for threatened preterm labour did not differ. More infectious neonatal morbidity was seen in the clindamycin group (5/83 vs 0/85; P &lt; 0.05).
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Clindamycin 2% vaginal cream given prophylactically to women with a spontaneous preterm birth in the preceding pregnancy did not prevent preterm delivery or reduce the number of admissions for threatened preterm labour. The neonatal infectious morbidity in the group treated with clindamycin was significantly higher and a major concern.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Obstetrics and Gynaecology, Diaconessenhuis Meppel, The Netherlands.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Vermeulen
      </lastname>
      <forename>
       G M
      </forename>
      <initials>
       GM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Bruinse
      </lastname>
      <forename>
       H W
      </forename>
      <initials>
       HW
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     Br J Obstet Gynaecol
    </medlineta>
    <nlmuniqueid>
     7503752
    </nlmuniqueid>
    <issnlinking>
     0306-5456
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anti-Bacterial Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Vaginal Creams, Foams, and Jellies
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      18323-44-9
     </registrynumber>
     <nameofsubstance>
      Clindamycin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <citationsubset>
    J
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BJOG. 2000 Feb;107(2):295-6
     </refsource>
     <pmid version="1">
      10688520
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anti-Bacterial Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Clindamycin
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Obstetric Labor, Premature
     </descriptorname>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy Complications, Infectious
     </descriptorname>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Vaginal Creams, Foams, and Jellies
     </descriptorname>
    </meshheading>
   </meshheadinglist>
   <otherid source="PIP">
    143303
   </otherid>
   <otherid source="POP">
    00290235
   </otherid>
   <otherabstract type="PIP">
    <abstracttext>
     This multi-center, randomized, double-blind, placebo-controlled trial aimed to determine whether prophylactic administration of clindamycin 2% vaginal cream can reduce the incidence of preterm birth in a high risk population.  A total of 168 eligible women attending the antenatal clinics of 12 hospitals in Netherlands participated in the study.  Clindamycin 2% vaginal cream was administered to 83 women, and placebo cream to 85 women, daily for 7 days at 26 and 32 weeks of gestation.  Results of the study showed no difference in the overall preterm birth between clindamycin (23%) and placebo (18%) in the intention-to-treat analysis.  In the subgroup, which completed the trial and administered all medication, more women delivered before 34 weeks in the clindamycin group (9%) compared to the placebo group (1.4%).  Moreover, occurrence of neonatal infectious morbidity was higher in the clindamycin group (5/83 vs. 0/85; P  0.05).  In conclusion, clindamycin 2% vaginal cream given prophylactically to women with a spontaneous preterm birth in the preceding pregnancy did not prevent preterm delivery or reduce the number of admissions for threatened preterm labor.
    </abstracttext>
   </otherabstract>
   <keywordlist owner="PIP">
    <keyword majortopicyn="Y">
     Antibiotics
    </keyword>
    <keyword majortopicyn="N">
     Demographic Factors
    </keyword>
    <keyword majortopicyn="N">
     Developed Countries
    </keyword>
    <keyword majortopicyn="Y">
     Double-blind Studies
    </keyword>
    <keyword majortopicyn="N">
     Drugs
    </keyword>
    <keyword majortopicyn="N">
     Europe
    </keyword>
    <keyword majortopicyn="N">
     Netherlands
    </keyword>
    <keyword majortopicyn="N">
     Population
    </keyword>
    <keyword majortopicyn="N">
     Population Characteristics
    </keyword>
    <keyword majortopicyn="N">
     Pregnancy
    </keyword>
    <keyword majortopicyn="N">
     Pregnancy Outcomes
    </keyword>
    <keyword majortopicyn="Y">
     Pregnant Women
    </keyword>
    <keyword majortopicyn="Y">
     Premature Birth--prevention and control
    </keyword>
    <keyword majortopicyn="N">
     Reproduction
    </keyword>
    <keyword majortopicyn="N">
     Research Methodology
    </keyword>
    <keyword majortopicyn="Y">
     Research Report
    </keyword>
    <keyword majortopicyn="N">
     Studies
    </keyword>
    <keyword majortopicyn="N">
     Treatment
    </keyword>
    <keyword majortopicyn="N">
     Western Europe
    </keyword>
   </keywordlist>
   <generalnote owner="PIP">
    TJ: BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY.
   </generalnote>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1999
     </year>
     <month>
      7
     </month>
     <day>
      31
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2000
     </year>
     <month>
      6
     </month>
     <day>
      10
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1999
     </year>
     <month>
      7
     </month>
     <day>
      31
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10428520
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

